UPDATE 1-Gilead asks FDA to revoke orphan drug status for potential coronavirus drug [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
UPDATE 1-Gilead asks FDA to revoke orphan drug status for potential coronavirus drug (Adds background, shares) March 25 (Reuters) - Gilead Sciences Inc said on Wednesday it had requested the U.S. Food and Drug Administration to rescind the “orphan drug” status for its experimental drug, remdesivir, seen as one of the more promising potential treatments for coronavirus, sending its shares down 4.4%. The orphan drug status provides a seven-year market exclusivity period, as well as tax and other incentives for drug companies developing treatments for rare diseases that affect fewer than 200,000 people. Senator Bernie Sanders has criticized U.S. President Donald Trump's administration for granting Gilead the seven-year exclusivity, and the drugmaker has also faced flak from health advocates. ( bit.ly/2Ujkqrl ) The drugmaker said it was confident of maintaining an expedited timeline for seeking regulatory review of remdesivir, without the orphan drug designation. Shares fell to $70.7 in a
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Autoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixBusiness Wire
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 3/28/24 - Form ARS
- 3/28/24 - Form DEF
- 3/28/24 - Form DEFA14A
- GILD's page on the SEC website